Bauml JM, et al. - In this single-arm phase 2 trial, researchers ascertained if the addition of pembrolizumab after locally ablative therapy (LAT) improves outcomes for patients with oligometastatic non–small cell lung cancer (NSCLC). Findings revealed that the median progression-free survival (PFS) was 19.1 months which was longer than historical data. According to findings, the use of pembrolizumab for oligometastatic NSCLC after LAT has been correlated with a clinically and statistically significant enhancement in PFS relative to historical data, suggesting further evaluation of this treatment in a randomized clinical trial. Overall, the authors concluded that pembrolizumab after LAT seems to enhance PFS for oligometastatic NSCLC without any decrease in quality of life.